A simple detection method for the serum sFLT1 protein in preeclampsia

[1]  Y. Çekmez,et al.  Maternal serum thrombospondin-1 is significantly altered in cases with established preeclampsia , 2019, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[2]  M. Shibuya,et al.  HIF-2α, but not HIF-1α, mediates hypoxia-induced up-regulation of Flt-1 gene expression in placental trophoblasts , 2018, Scientific Reports.

[3]  H. Prömpeler,et al.  Treatment of very preterm preeclampsia via heparin-mediated extracorporeal LDL-precipitation (H.E.L.P.) apheresis: The Freiburg preeclampsia H.E.L.P.-Apheresis study. , 2018, Pregnancy hypertension.

[4]  I. Merfort,et al.  Lipoprotein turnover and possible remnant accumulation in preeclampsia: insights from the Freiburg Preeclampsia H.E.L.P.-apheresis study , 2018, Lipids in Health and Disease.

[5]  J. Xu,et al.  Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia , 2017, Hypertension in pregnancy.

[6]  R. van der Does,et al.  Influence of the sFlt-1/PlGF Ratio on Clinical Decision-Making in Women with Suspected Preeclampsia , 2016, PloS one.

[7]  T. Benzing,et al.  Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. , 2016, Journal of the American Society of Nephrology : JASN.

[8]  I. Konishi,et al.  Case of soluble fms‐like tyrosine kinase 1 apheresis in severe pre‐eclampsia developed at 15 weeks’ gestation , 2015, The journal of obstetrics and gynaecology research.

[9]  D. Armant,et al.  Reduced expression of the epidermal growth factor signaling system in preeclampsia. , 2015, Placenta.

[10]  R. van der Does,et al.  Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia – the PreOS study protocol , 2015, Hypertension in pregnancy.

[11]  J. Kingdom,et al.  Altered hemodynamics and hyperuricemia accompany an elevated sFlt-1/PlGF ratio before the onset of early severe preeclampsia. , 2014, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[12]  Dean Y. Li,et al.  Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1 , 2013, eLife.

[13]  O. Shaker,et al.  Pathogenesis of preeclampsia , 2013, Human & experimental toxicology.

[14]  P. Sarkar,et al.  Association of antithrombin-III and platelet count with pregnancy induced hypertension , 2013 .

[15]  M. Shibuya,et al.  Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. , 2013, Journal of biochemistry.

[16]  T. Pawson,et al.  Soluble FLT1 Binds Lipid Microdomains in Podocytes to Control Cell Morphology and Glomerular Barrier Function , 2012, Cell.

[17]  Santosh A. Khedkar,et al.  Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia , 2011, Circulation.

[18]  J. V. D. van der Post,et al.  Expression of Placental FLT1 Transcript Variants Relates to Both Gestational Hypertensive Disease and Fetal Growth , 2011, Hypertension.

[19]  M. Shibuya.  Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[20]  R. Levine,et al.  Pathogenesis of preeclampsia. , 2010, Annual review of pathology.

[21]  F. Chantraine,et al.  Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer. , 2009, Journal of reproductive immunology.

[22]  Kang Z. Liu,et al.  A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. , 2009, The Journal of clinical endocrinology and metabolism.

[23]  S. Lim,et al.  Preeclampsia: the role of angiogenic factors in its pathogenesis. , 2009, Physiology.

[24]  L. Florea,et al.  Novel splice variants of sFlt1 are upregulated in preeclampsia. , 2009, Placenta.

[25]  A. Jeyabalan,et al.  Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. , 2009, Placenta.

[26]  J. Foidarta,et al.  Dysregulation of anti-angiogenic agents ( sFlt-1 , PLGF , and sEndoglin ) in preeclampsia — a step forward but not the definitive answer , 2009 .

[27]  S. Yagel,et al.  A Novel Human-Specific Soluble Vascular Endothelial Growth Factor Receptor 1: Cell Type-Specific Splicing and Implications to Vascular Endothelial Growth Factor Homeostasis and Preeclampsia , 2008, Circulation research.

[28]  J. Foidart,et al.  Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. , 2008, Human reproduction.

[29]  Kang Z. Liu,et al.  Intronic polyadenylation signal sequences and alternate splicing generate human soluble Fltl variants and regulate the abundance of soluble Flt1 in the placenta , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  G. Saade,et al.  The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. , 2007, American journal of obstetrics and gynecology.

[31]  M. Shibuya.  Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis , 2006, Angiogenesis.

[32]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[33]  S. Kōzuma,et al.  Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. , 2004, Endocrinology.

[34]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[35]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[36]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[37]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.

[38]  Y. Taketani,et al.  Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. , 2003, The Journal of clinical endocrinology and metabolism.

[39]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[40]  K. Shitara,et al.  Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells , 2000, Oncogene.

[41]  D. Charnock-Jones,et al.  Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. , 1999, Molecular endocrinology.

[42]  A. N. Corps,et al.  A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. , 1998, Biology of reproduction.

[43]  M. Shibuya,et al.  Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. , 1998, Gene.

[44]  M. Shibuya,et al.  Characterization of the Extracellular Domain in Vascular Endothelial Growth Factor Receptor‐1 (Flt‐1 Tyrosine Kinase) , 1997, Japanese journal of cancer research : Gann.

[45]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.